Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 ...